News

7 August 2017 - Just Published: article on NLX-112 analgesic activity in mouse

The Neurolixis drug candidate for treatment of dyskinesia (LID) in Parkinson's disease, NLX-112, was tested in a new study of analgesic activity. It exhibited potent analgesic activity in the mouse formalin test, a model of tonic pain, possibly through activation of spinal cord serotonin 5-HT1A receptors. NLX-112 was also active, albeit less potently, in other pain tests suggesting that it may have beneficial properties on chronic pain symptoms in Parkinson's disease, in addition to its potent anti-dyskinetic activity against L-DOPA-induced dyskinesia (LID), as previously described.

Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain

Sałat K, Kołaczkowski M, Furgała A, Rojek A, Śniecikowska J, Varney MA, Newman-Tancredi A
Neuropharmacology. 2017 Jul 24;125:181-188. doi: 10.1016/j.neuropharm.2017.07.022.

 

14 June 2017 - Just Published: article on NLX-112 agonist properties in vitro

A new publications characterizes the distinctive in vitro agonist properties of NLX-112, a potential drug therapy for L-DOPA-induced dyskinesia (LID) in Parkinson's disease. NLX-112 was tested in a variety of in vitro assays of serotonin 5-HT1A receptor activation and consistently exhibited very high agonist efficacy. NLX-112 also exhibited preferential activation of a specific G-protein subtype (Go), unlike other compounds such as NLX-101, which is being developed by Neurolixis for Rett syndrome. Overall, the study provides further pharmacological support for the superior profile of NLX-112 compared to previous serotonergic agonists.

Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist

Newman-Tancredi A, Martel J-C, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D.
Journal of Pharmacy and Pharmacology, 2017 June 14. DOI: 10.1111/jphp.12762